A Phase 3 interventional study of quinolone in Bacterial Conjunctivitis, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2009-09-29.
Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment
The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.
40 studies on the registry are indexed under Conjunctivitis, Bacterial; 2 are open to participants now.
This study's planned enrollment of 600 is above the median of 261 across 36 interventional studies indexed under Conjunctivitis, Bacterial.
Browse Conjunctivitis, Bacterial studies →Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Clinical cure and microbiological success
Individual signs and symptoms of bacterial conjunctivitis at each visit
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.